Skip to main content
Premium Trial:

Request an Annual Quote

Geneart's First-Half '09 Sales Rise 3 Percent

NEW YORK (GenomeWeb News) – Geneart today reported that its sales for the first half of 2009 increased 3 percent to €8.1 million ($11.6 million) from €7.9 million for the first half of 2008.

The Regensburg, Germany-based gene synthesis firm said that its EBITDA for the first half was €800,000 versus €1.4 million for the comparable period a year ago.

"[D]espite difficult market environment, Geneart managed to compensate for the expiring major contract by the NIH … in the third quarter 2008 by an increasing number of medium-sized and small orders," the firm said in a statement.

Geneart said that it expects net sales of €16 million for full-year 2009, but that could rise to between €17 million and €18 million if the economic environment improves during the second half of this year.

Filed under

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.